Ivan Cornella, PhD

Before founding Covant Therapeutics, throughout his career, Ivan consulted on target enablement and drug discovery for a number of start-ups and biotech firms. In previous roles, at Roivant Discovery, Cedilla Therapeutics, Merck, AstraZeneca, Sanofi, and Novartis, Ivan established and managed translational chemical biology and proteomics teams, supporting target discovery and validation, and lead finding initiatives across disease areas, target classes, and modalities.
Ivan holds a Ph.D. in organic chemistry from the Universidade da Coruña, Spain, and earned an Executive Certificate in innovation from MIT Sloan School of Management. He completed postdoctoral work at the Institute of Chemistry & Cell Biology of Harvard Medical School (now the Broad Institute of MIT and Harvard), as National Cancer Institute Initiative for Chemical Genetics Research Fellow, and at the Boston College chemistry department.
Ivan is an active member of the AACR Chemistry in Cancer Research (CICR) committee, and an ambassador for non-profit organization Seeding Labs.